In preclinical studies, topically applied GM-1111 significantly reduced the clinical signs of CRS. Concurrent reduction of inflammatory molecules within the tissue treated with GM-1111 suggest the therapeutic potentials in CRS patients. In addition, GM-1111 has mucolytic properties that can enhance its therapeutic effects in severe cases of CRS with cystic fibrosis (CF).
GlycoMira Announces Phase IIB Bridge Grant Award ($2M) from the NIH (NIAID) for Continuing Efforts to Develop the Company’s Lead Candidate Drug GM-1111 as a Therapeutic for Chronic Rhinosinusitis (CRS)
(Salt Lake City, UT, June 24, 2021) GlycoMira Therapeutics announced that it has received a competitive $2M award from the National Institutes of Health to support the completion of IND-enabling studies for a treatment to provide relief to the millions of people who suffer daily with chronic rhinosinusitis (CRS). Afflicting about 28.9 million US adults (CDC data), CRS manifests debilitating clinical signs causing serious declines in quality of life yet the therapeutic options have been largely limited to nasal irrigation, steroids, and surgery. GlycoMira has been developing a nonsteroidal therapeutic solution to address this largely unmet medical need. GlycoMira’s GM-1111 is a synthetic glycosaminoglycan-based drug that inhibits pattern recognition receptors (PRRs). PRRs are part of innate immune molecules responsible for initial tissue signaling of inflammation as well as amplification of disease progression that typically occurs in various chronic inflammatory diseases.
About GlycoMira:
Located in Salt Lake City, GlycoMira is a development stage company that specializes in synthetic glycosaminoglycan-based technologies started from the University of Utah. GM-1111 has been developed for oncology (an anticancer drug that can also significantly reduce the adverse effects of cancer therapy) and respiratory indications (CRS and CF).
© GlycoMira Therapeutics, Inc.
All rights reserved.